SEARCH

SEARCH BY CITATION

References

  • Akin, C., Brockow, K., D’Ambrosio, C., Kirshenbaum, A.S., Ma, Y., Longley, B.J. & Metcalfe, D.D. (2003) Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated KIT. Experimental Hematology, 31, 686692.
  • Ashman, L.K., Ferrao, P., Cole, S.R. & Cambareri, A.C. (1999) Effects of mutant c-Kit in early myeloid cells. Leukaemia & Lymphoma, 34, 451461.
  • Brummelkamp, T.R., Bernards, R. & Agami, R. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2, 243247.
  • Butterfield, J.H., Weiler, D., Dewald, G. & Gleich, G.J. (1988) Establishment of an immature mast cell line from a patient with mast cell leukemia. Leukemia Research, 12, 345355.
  • Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Reviews. Drug discovery, 1, 493502.
  • Clarke, A.R., Purdie, C.A., Harrison, D.J., Morris, R.G., Bird, C.C., Hooper, M.L. & Wyllie, A.H. (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature, 362, 849852.
  • Dalen, H. & Neuzil, J. (2003) Alpha-tocopheryl succinate sensitises a T lymphoma cell line to TRAIL-induced apoptosis by suppressing NF-kappaB activation. British Journal of Cancer, 88, 153158.
  • Duursma, A.M. & Agami, R. (2003) Ras interference as cancer therapy. Seminars in Cancer Biology, 13, 267273.
  • Escribano, L., Akin, C., Castells, M., Orfao, A. & Metcalfe, D.D. (2002) Mastocytosis: current concepts in diagnosis and treatment. Annals of Hematology, 81, 677690.
  • Garcia-Montero, A.C., Jara-Acevedo, M., Teodosio, C., Sanchez, M.L., Nunez, R., Prados, A., Aldanondo, I., Sanchez, L., Dominguez, M., Botana, L.M., Sanchez-Jimenez, F., Sotlar, K., Almeida, J., Escribano, L. & Orfao, A. (2006) KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood, 108, 23662372.
  • Haller, F., Detken, S., Schulten, H.J., Happel, N., Gunawan, B., Kuhlgatz, J. & Fuzesi, L. (2007) Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations. Annals of Surgical Oncology, 14, 526532.
  • Hartmann, K., Wardelmann, E., Ma, Y., Merkelbach-Bruse, S., Preussner, L.M., Woolery, C., Baldus, S.E., Heinicke, T., Thiele, J., Buettner, R. & Longley, B.J. (2005) Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology, 129, 10421046.
  • Hines, S.J., Organ, C., Kornstein, M.J. & Krystal, G.W. (1995) Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth and Differentiation, 6, 769779.
  • Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., Muhammad Tunio, G., Matsuzawa, Y., Kanakura, Y., Shinomura, Y. & Kitamura, Y. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science, 279, 577580.
  • Inoue, M., Kyo, S., Fujito, M., Enomoto, T. & Kondoh, G. (1994) Coexpression of c-kit receptor and the stem cell factor receptor in gynecological tumors. Cancer Research, 54, 30493053.
  • Jaattela, M., Wissing, D., Kokholm, K., Kallunki, T. & Egeblad, M. (1998) Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO Journal, 17, 61246134.
  • Johnson, F.M., Krug, L.M., Tran, H.T., Shoaf, S., Prieto, V.G., Tamboli, P., Peeples, B., Patel, J. & Glisson, B.S. (2006) Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer, 106, 366374.
  • Kempna, P., Reiter, E., Arock, M., Azzi, A. & Zingg, J.M. (2004) Inhibition of HMC-1 mast cell proliferation by vitamin E: involvement of the protein kinase B pathway. Journal of Biological Chemistry, 279, 5070050709.
  • Kim, D.H. & Rossi, J.J. (2007) Strategies for silencing human disease using RNA interference. Nature Reviews. Genetics, 8, 173184.
  • Krystal, G.W., Hines, S.J. & Organ, C.P. (1996) Autocrine growth of small cell lung cancer mediated by co-expression of c-kit ans stem cell factor. Cancer Research, 56, 370376.
  • Lim, S.J., Lee, Y.J., Park, D.H., Lee, E., Choi, M.K., Park, W., Chun, K.H., Choi, H.G. & Cho, J.S. (2007) Alpha-tocopheryl succinate sensitizes human colon cancer cells to exisulind-induced apoptosis. Apoptosis, 12, 423431.
  • Longley, B.J., Reguera, M.J. & Ma, Y. (2001) Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leukemia Research, 25, 571576.
  • Ma, Y., Longley, B.J., Wang, X., Blount, J.L., Langley, K. & Caughey, G.H. (1999) Clustering of activating mutations in c-KIT’s juxtamembrane coding region in canine mast cell neoplasms. Journal of Investigative Dermatology, 112, 165170.
  • Martinez, L.A., Naguibneva, I., Lehrmann, H., Vervisch, A., Tchenio, T., Lozano, G. & Harel-Bellan, A. (2002) Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proceedings of the National Academy of Sciences of the United States of America, 99, 1484914854.
  • McLean, S.R., Gana-Weisz, M., Hartzoulakis, B., Frow, R., Whelan, J., Selwood, D. & Boshoff, C. (2005) Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Molecular Cancer Therapeutics, 4, 20082015.
  • Mol, C.D., Dougan, D.R., Schneider, T.R., Skene, R.J., Kraus, M.L., Scheibe, D.N., Snell, G.P., Zou, H., Sang, B.C. & Wilson, K.P. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. Journal of Biological Chemistry, 279, 3165531663.
  • Neuzil, J., Kagedal, K., Andera, L., Weber, C. & Brunk, U.T. (2002) Vitamin E analogs: a new class of multiple action agents with anti-neoplastic and anti-atherogenic activity. Apoptosis, 7, 179187.
  • Neuzil, J., Tomasetti, M., Zhao, Y., Dong, L.F., Birringer, M., Wang, X.F., Low, P., Wu, K., Salvatore, B.A. & Ralph, S.J. (2007) Vitamin E analogs, a novel group of “mitocans,” as anticancer agents: the importance of being redox-silent. Molecular Pharmacology, 71, 11851199.
  • Olivieri, A. & Manzione, L. (2007) Dasatinib: a new step in molecular target therapy. Annals of Oncology, 18(Suppl. 6), vi42vi46.
  • Orfao, A., Garcia-Montero, A.C., Sanchez, L. & Escribano, L. (2007) Recent advances in the understanding of mastocytosis: the role of KIT mutations. British Journal of Haematology, 138, 1230.
  • Perez-Soler, R. (2007) Erlotinib: recent clinical results and ongoing studies in non small cell lung cancer. Clinical Cancer Research, 13, s4589s4592.
  • Prasad, K.N., Hernandez, C., Edwards-Prasad, J., Nelson, J., Borus, T. & Robinson, W.A. (1994) Modification of the effect of tamoxifen, cis-platin, DTIC, and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutrition and Cancer, 22, 233245.
  • Quintas-Cardama, A., Aribi, A., Cortes, J., Giles, F.J., Kantarjian, H. & Verstovsek, S. (2006) Novel approaches in the treatment of systemic mastocytosis. Cancer, 107, 14291439.
  • Raoul, C., Abbas-Terki, T., Bensadoun, J.C., Guillot, S., Haase, G., Szulc, J., Henderson, C.E. & Aebischer, P. (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nature Medicine, 11, 423428.
  • Rosato, R.R., Almenara, J.A. & Grant, S. (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Research, 63, 36373645.
  • Roucou, X., Montessuit, S., Antonsson, B. & Martinou, J.C. (2002) Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein. Biochemical Journal, 368, 915921.
  • Ruano, I. & Izquierdo, M. (2009) Selective RNAi-mediated inhibition of mutated c-kit. Journal of RNAi and Gene Silencing, 5, 339344.
  • Simbulan-Rosenthal, C.M., Rosenthal, D.S., Iyer, S., Boulares, H. & Smulson, M.E. (1999) Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication. Molecular and Cellular Biochemistry, 193, 137148.
  • Tomasetti, M., Rippo, M.R., Alleva, R., Moretti, S., Andera, L., Neuzil, J. & Procopio, A. (2004) Alpha-tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells. British Journal of Cancer, 90, 16441653.
  • Tomasetti, M., Andera, L., Alleva, R., Borghi, B., Neuzil, J. & Procopio, A. (2006) Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Letters, 580, 19251931.
  • Uriarte, S.M., Joshi-Barve, S., Song, Z., Sahoo, R., Gobejishvili, L., Jala, V.R., Haribabu, B., McClain, C. & Barve, S. (2005) Akt inhibition upregulates FasL, downregulates c-FLIPs and induces caspase-8-dependent cell death in Jurkat T lymphocytes. Cell Death and Differentiation, 12, 233242.
  • Valent, P., Akin, C., Sperr, W.R., Mayerhofer, M., Födinger, M., Fritsche-Polanz, R., Sotlar, K., Escribano, L., Arock, M., Horny, H.P. & Metcalfe, D.D. (2005) Mastocytosis: pathology, genetics, and current options for therapy. Leukaemia & Lymphoma, 46, 3548.
  • Vitali, R., Cesi, V., Nicotra, M.R., Donfrancesco, A., McDowell, H.P., Mannarino, O., Natali, P.G., Raschella, G. & Dominici, C. (2003) c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited by STI-571. International Journal of Cancer, 106, 147152.
  • Weber, T., Lu, M., Andera, L., Lahm, H., Gellert, N., Fariss, M.W., Korinek, V., Sattler, W., Ucker, D.S., Terman, A., Schroder, A., Erl, W., Brunk, U.T., Coffey, R.J., Weber, C. & Neuzil, J. (2002) Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. Clinical Cancer Research, 8, 863869.
  • Xu, Z.W., Friess, H., Buchler, M.W. & Solioz, M. (2002) Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemotherapy and Pharmacology, 49, 504510.
  • Yu, W., Israel, K., Liao, Q.Y., Aldaz, C.M., Sanders, B.G. & Kline, K. (1999) Vitamin E succinate (VES) induces Fas sensitivity in human breast cancer cells: role for Mr 43,000 Fas in VES-triggered apoptosis. Cancer Research, 59, 953961.
  • Zermati, Y., De Sepulveda, P., Feger, F., Letard, S., Kersual, J., Casteran, N., Gorochov, G., Dy, M., Ribadeau Dumas, A., Dorgham, K., Parizot, C., Bieche, Y., Vidaud, M., Lortholary, O., Arock, M., Hermine, O. & Dubreuil, P. (2003) Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms. Oncogene, 22, 660664.